Claimed effect · Tirzepatide

Does Tirzepatide help with blood glucose?

A
Grade A — established in humans5 SURPASS RCTs · effect size: large
Short answerEstablished in humans. 5 SURPASS RCTs point the same way: a large effect. SURPASS-2: HbA1c reductions of 2.0–2.3 points vs 1.9 on semaglutide 1 mg in type 2 diabetes.

What the studies show

SURPASS-2: HbA1c reductions of 2.0–2.3 points vs 1.9 on semaglutide 1 mg in type 2 diabetes.

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
    Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2).N Engl J Med, 2021;385:503–5151,879 adults; HbA1c and weight vs semaglutide 1 mg.

In context

Tirzepatide is a once-weekly peptide that activates both GIP and GLP-1 receptors. It is approved for type 2 diabetes, weight management and obstructive sleep apnoea, and in the only direct head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks) with a similar side-effect profile. It is a prescription medicine; versions sold outside that channel are unlicensed.

Tirzepatide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Tirzepatide proven to help with blood glucose?
Yes, as far as human trials can show it: 5 SURPASS RCTs. LYO grades this outcome A.
What studies are behind the grade?
SURPASS-2: HbA1c reductions of 2.0–2.3 points vs 1.9 on semaglutide 1 mg in type 2 diabetes.
Is Tirzepatide approved for this?
Tirzepatide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Tirzepatide

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →